Loading
companiesCompany
Invocata
Invocata is building personalised T-cell receptor therapies, choosing the right TCR for the individual patient at the right time; its site says only that it is coming soon.
Overview
Invocata describes personalised oncology platforms designed for the individual, moving cancer care towards an N of 1, with T-cell receptor (TCR) therapy as its route: engineering a patient's T cells to carry a receptor that recognises their own tumour. The public site is a placeholder. It is an Even One Ventures portfolio company.
Headquarters
United States (head office not published), US
Funding
All startupsStartup
Investors
Type
Stage
Startup
Website
Similar pages
- CompanyRanata Therapeutics
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
- CompanyRelit Biosciences
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
- CompanyEcho Immune
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
- CompanyMinuteman Therapeutics
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
- CompanyYuga Bio
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
- CompanyKernis Health
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
- CompanyPalitra Bio
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
- CompanyArden Bio
Shares Even One Ventures and the tags startup, evenone-portfolio.